• 1
    Dykewicz MS, Fineman S, Skoner DP, Nicklas R, Lee R, Blessing-Moore J et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998;81:478518.
  • 2
    Bachert C, Van Cauwenberge P, Olbrecht J, Van Schoor J. Prevalence, classification and perception of allergic and nonallergic rhinitis in Belgium. Allergy 2006;61:693698.
  • 3
    Bousquet J, Van Cauwenberge P, Ait Khaled N, Bachert C, Baena-Cagnani CE, Bouchard J et al. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN). Allergy Eur J Allergy Clin Immunol 2006;61:10861096.
  • 4
    Frieri M. Inflammatory issues in allergic rhinitis and asthma. Allergy Asthma Proc 2005;26:163169.
  • 5
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147S334.
  • 6
    Van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116134.
  • 7
    Task Force on Allergic Disorders. The Allergy Report, Vol. 1. Milwaukee, WI: American Academy of Allergy, Asthma and Immunology, 2000.; accessed 21 June 2007.
  • 8
    Allen DB. Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106:S179S190.
  • 9
    Passalacqua G, Albano M, Canonica GW, Bachert C, Van Cauwenberge P, Davies RJ et al. Inhaled and nasal corticosteroids: safety aspects. Allergy 2000;55:1633.
  • 10
    Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739750.
  • 11
    Allen A, Down G, Newlands A, Rousell V, Salmon E. Tolerability, safety, pharmacokinetics and bioavailability of the novel intranasal corticosteroid fluticasone furoate in healthy subjects. Ann Allergy Asthma Immunol 2007;98:A89.
  • 12
    Martin BG, Ratner PH, Hampel FC, Andrews CP, Toler T, Wu W et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc 2007;28:216225.
  • 13
    National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the diagnosis and management of asthma: update on selected topics. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute, 2002.
  • 14
    Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MD: National Institutes of Health, 2004 (NIH Publication No. 02-3659).
  • 15
    European Medicines Agency. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions. London: European Medicines Agency, 1995 (CPMP/ICH/375/95).
  • 16
    Salib RJ, Howarth PH. Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Saf 2003;26:863893.
  • 17
    Waddell AN, Patel SK, Toma AG, Maw AR. Intranasal steroid sprays in the treatment of rhinitis: is one better than another? J Laryngol Otol 2003;117:843845.
  • 18
    Benninger MS, Hadley JA, Osguthorpe JD, Marple BF, Leopold DA, Derebery MJ et al. Techniques of intranasal steroid use. Otolaryngol Head Neck Surg 2004;130:524.
  • 19
    Van As A, Bronsky EA, Dockhorn RJ, Grossman J, Lumry W, Meltzer EO et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol 1993;91:11461154.
  • 20
    Drouin M, Yang WH, Bertrand B, Van Cauwenberge P, Clement P, Dalby K et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 1996;77:153160.
  • 21
    Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 1997;79:237245.
  • 22
    Schering Data on File: Trial C94-052. Efficacy and safety of mometasone furoate nasal spray vs fluticasone propionate nasal spray and vs placebo in the treatment of perennial allergic rhinitis (PAR). From summary basis of approval (SBA) for Nasonex. 2007. Available at:, accessed on 21 June 2007.
  • 23
    Schering Data on File: Trial C93-014. Long-term safety of mometasone furoate nasal spray in the treatment of perennial allergic rhinitis (PAR). From summary basis of approval (SBA) for Nasonex. 2007. Available at:, accessed on 21 June 2007.
  • 24
    Bachert C, Lukat KF, Lange B. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin Exp Allergy 2004;34:8590.
  • 25
    Nathan RA, Bronsky EA, Fireman P, Grossman J, LaForce CF, Lemanske RF Jr et al. Once daily fluticasone propionate aqueous nasal spray is an effective treatment for seasonal allergic rhinitis. Ann Allergy 1991;67:332338.
  • 26
    Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol 1998;102:191197.
  • 27
    Sheth KK, Cook CK, Philpot EE, Prillaman BA, Witham LA, Faris MA et al. Concurrent use of intranasal and orally inhaled fluticasone propionate does not affect hypothalamic-pituitary-adrenal-axis function. Allergy Asthma Proc 2004;25:115120.
  • 28
    Nave R, Wingertzahn MA, Brookman S, Kaida S, Matsunaga T. Safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis. J Clin Pharmacol 2006;46:461467.